Literature DB >> 9327353

Ophthalmic generic drug approval process: implications for efficacy and safety.

L B Cantor1.   

Abstract

Mesh：

Substances：

Year:  1997        PMID： 9327353     DOI： 10.1097/00061198-199710000-00011

Source DB:  PubMed          Journal:  J Glaucoma        ISSN： 1057-0829            Impact factor:   2.503


× No keyword cloud information.
  5 in total

1.  Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.

Authors:  Paula Anne Newman-Casey; Maria A Woodward; Leslie M Niziol; Paul P Lee; Lindsey B De Lott
Journal:  Ophthalmology       Date:  2017-06-16       Impact factor: 12.079

2.  [Original preparations versus generics--latanoprost: how similar is different?].

Authors:  M A Leitritz; H-P Lipp; B Voykov; F Ziemssen
Journal:  Ophthalmologe       Date:  2015-02       Impact factor: 1.059

3.  The Effect of Market Competition on the Price of Topical Eye Drops.

Authors:  Arjun Watane; Meghana Kalavar; Joshua Reyes; Nicolas A Yannuzzi; Jayanth Sridhar
Journal:  Semin Ophthalmol       Date:  2021-03-29       Impact factor: 1.975

Review 4.  The Use of Generic Medications for Glaucoma.

Authors:  Andrew J Tatham
Journal:  J Ophthalmol       Date:  2020-04-07       Impact factor: 1.909

5.  Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations.

Authors:  Dewang Angmo; Meenakshi Wadhwani; Thirumurthy Velpandian; Ankita Kotnal; Ramanjit Sihota; Tanuj Dada
Journal:  Int Ophthalmol       Date:  2016-06-22       Impact factor: 2.031
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.